Meeting Banner
Abstract #0708

Hyperpolarized 13C MRI of Patients with Metastatic Prostate Cancer to Bone and Liver

Hsin-Yu Chen1, Philip Lee1, Zi Zhu1, Robert A. Bok1, Michael A. Ohliger1, Jeremy W. Gordon1, Mark van Criekinge1, Lucas Carvajal1, James B. Slater1, Peder E.Z. Larson1, Pamela N. Munster2, Rahul Aggarwal2, John Kurhanewicz1, and Daniel B. Vigneron1

1Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, 2School of Medicine, University of California, San Francisco, San Francisco, CA, United States

In this feasibility study, hyperpolarized 13C-pyruvate MR exams were conducted on 5 patients who had metastatic prostate cancer to bone or liver. In one man with liver metastasis, serial scans showed a decrease of pyruvate-to-lactate conversion kPL (0.026 to 0.015 s-1) at 2 months after initiation of chemotherapy that was consistent with response based on PSA and RECIST criteria. High kPL was found in patients with bone lesions comparable to that in high-grade primary prostate cancer. Overall, HP-13C MR imaging showed great promise as a biomarker to evaluating treatment responses in metastatic prostate cancer.

This abstract and the presentation materials are available to members only; a login is required.

Join Here